- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05024552
Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML
A Phase 1 Study of Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated Acute Myeloid Leukemia
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33612
- Recruiting
- Moffitt Cancer Center
-
Sub-Investigator:
- Jeffrey E Lancet, MD
-
Sub-Investigator:
- Eric Padron, MD
-
Sub-Investigator:
- Brandon Blue, MD
-
Sub-Investigator:
- David A Sallman, MD
-
Contact:
- Jhada-Kai Hunter
- Phone Number: 813-745-0286
- Email: Jhada-Kai.Hunter@moffitt.org
-
Sub-Investigator:
- Timothy Kubal, MD, MBA
-
Principal Investigator:
- Onyee Chan, MD
-
Sub-Investigator:
- Andrew T Kuykendall, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Eastern Cooperative Oncology Group (ECOG) performance status ≤2
- FLT3-ITD or FLT3-TKD mutated AML (non-M3) in 1st or greater relapse or refractory to at least one prior line of AML directed therapy
- FLT3 testing must be confirmed at the time of disease relapse
- Adequate organ function
- Left ventricular ejection fraction (LVEF) ≥50%
- Prior anthracycline exposure ≤368 mg/m2 daunorubicin (or equivalent)
- Ability to take oral medication and willingness to adhere to the medication regimen
- For females of reproductive potential: use of highly effective contraception including double barrier methods (condoms with spermicidal jelly or foam and diaphragm with spermicidal jelly or foam), oral, depo provera, or injectable contraceptives, intrauterine devices and tubal ligation.
- For females of reproductive potential: negative serum or urine pregnancy test with a sensitivity of at least 50mIU/mL within 10 days and again within 24 hours of beginning study treatment
- For males of reproductive potential: use of condoms
- Breastfeeding mothers must agree to discontinue nursing
- Patients who have relapsed after and allogeneic stem cell transplant must have controlled grade ≤2 GVHD. Immunosuppression with tacrolimus or sirolimus is allowed at stable or tapering doses.
Exclusion Criteria:
- Patients may not be receiving any other investigational agents
- Patients with documented central nervous system involvement of AML
- Progression of AML while on prior gilteritinib therapy
- Patients must not have evidence of GI tract abnormalities that would alter the absorption of oral medications
- Major surgery within two weeks of first dose of study drug. Patients must have recovered from the effects of any surgery performed greater than two weeks prior
- WBC count ≥50,000 at the time study treatment begins. Use of hydroxyurea to maintain WBC <50,000 is allowed up to the time that study treatment begins
- Predicted inability to tolerate standard induction chemotherapy
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- No other malignancies in addition to AML that are currently requiring treatment with the exception of: 1) basal cell or squamous cell carcinoma or the skin; 2) carcinoma in situ of the cervix or breast; 3) a history of breast cancer that is currently being managed with adjuvant endocrine therapy
- Grade ≥3 acute or chronic graft versus host disease after allogeneic stem cell transplant. No steroids for GVHD are allowed.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose Escalation Arm
Participants will receive intravenous Vyxeos on days 1, 3 and 5 and Gilteritinib will be given on days 6-19 of induction therapy. The induction and reinduction dose of Vyxeos is 44mg/m2 daunorubicin and 100mg/m2 of cytarabine with each infusion. Dose level 1: Vyxeos + 120 mg Gilertinib In the event of a dose-limiting toxicity (DLT) at the initial dose level, a dose level minus (-) 1 is permitted Dose Level -1: Vyxeos + 80 mg Gilertinib |
Gilteritinib is an oral inhibitor of FLT3-ITD and FLT3-TKD.
Dose cohort 1 will receive 120mg daily on days 6-19 of induction and days 4-17 of re-induction and consolidation
Other Names:
Vyxeos is a liposomal encapsulation of cytarabine and daunorubicin.
It is given as an intravenous infusion over 90 minutes on days 1, 3 and 5 of induction and days 1 and 3 of re-induction and consolidation.
The induction and reinduction dose is 44mg/m2 daunorubicin and 100mg/m2 of cytarabine with each infusion.
The consolidation dose is 29mg/m2 daunorubicin and 65mg/m2 of cytarabine with each dose.
Other Names:
|
Experimental: Dose Expansion Arm
Participants will receive intravenous Vyxeos on days 1, 3 and 5 and Gilteritinib will be given on days 6-19 of induction therapy in the dose determined in the dose escalation arm.
|
Gilteritinib is an oral inhibitor of FLT3-ITD and FLT3-TKD.
Dose cohort 1 will receive 120mg daily on days 6-19 of induction and days 4-17 of re-induction and consolidation
Other Names:
Vyxeos is a liposomal encapsulation of cytarabine and daunorubicin.
It is given as an intravenous infusion over 90 minutes on days 1, 3 and 5 of induction and days 1 and 3 of re-induction and consolidation.
The induction and reinduction dose is 44mg/m2 daunorubicin and 100mg/m2 of cytarabine with each infusion.
The consolidation dose is 29mg/m2 daunorubicin and 65mg/m2 of cytarabine with each dose.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose (MTD)
Time Frame: Up to 18 months
|
Dose escalation will determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Vyxeos plus Gilteritinib.
The MTD is the highest dose of the combination therapy that dose not cause unacceptable side effects.
|
Up to 18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete Remission Rate
Time Frame: Up to 18 months
|
Rate of complete remission (CR) and complete remission with incomplete blood count recovery (CRi).
The definition of CR and CRi is based on the European LeukemiaNet 2017 Response Criteria
|
Up to 18 months
|
Event free survival (EFS)
Time Frame: Up to 18 months
|
Event free survival is determined as the duration of time from start of treatment to the time of cancer recurrence.
|
Up to 18 months
|
Overall survival (OS)
Time Frame: Up to 5 years
|
Overall survival is defined as the duration of time from start of treatment to the time of death from any cause or date of last contact.
|
Up to 5 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Onyee Chan, MD, Moffitt Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Cytarabine
- Daunorubicin
Other Study ID Numbers
- MCC-20752
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia With FLT3/ITD Mutation
-
Gruppo Italiano Malattie EMatologiche dell'AdultoRecruitingAcute Myeloid Leukemia With FLT3/ITD MutationItaly
-
The First Affiliated Hospital of Soochow UniversityUnknown
-
Shijiazhuang Yiling Pharmaceutical Co. LtdNot yet recruitingAcute Myeloid Leukemia With FLT3/ITD Mutation
-
Mayo ClinicNational Cancer Institute (NCI)TerminatedSecondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Acute Myeloid Leukemia With FLT3/ITD Mutation | Acute Myeloid Leukemia With Gene Mutations | FLT3 Tyrosine Kinase Domain Point MutationUnited States
-
Nanfang Hospital of Southern Medical UniversityXiangya Hospital of Central South University; Peking University People's Hospital and other collaboratorsCompletedAcute Myeloid Leukemia | Hematopoietic Stem Cell Transplantation | Acute Myeloid Leukemia With FLT3/ITD MutationChina
-
Nanfang Hospital of Southern Medical UniversityRecruitingAllogeneic Hematopoietic Stem Cell Transplantation | Acute Myeloid Leukemia With FLT3/ITD MutationChina
-
Nanfang Hospital of Southern Medical UniversityRecruitingAllogeneic Hematopoietic Stem Cell Transplantation | Acute Myeloid Leukemia With FLT3/ITD MutationChina
-
National Cancer Institute (NCI)CompletedTherapy-Related Acute Myeloid Leukemia | Acute Myeloid Leukemia With FLT3/ITD Mutation | FLT3 Gene Mutation | Acute Promyelocytic Leukemia With PML-RARA | Acute Myeloid Leukemia With Inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 | Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1United States
-
National Cancer Institute (NCI)CompletedAcute Myeloid Leukemia With FLT3/ITD MutationUnited States
-
Uma BorateRecruitingRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia With FLT3/ITD Mutation | Acute Myeloid Leukemia With KMT2A Rearrangement | Acute Myeloid Leukemia With NPM1 MutationUnited States
Clinical Trials on Gilteritinib
-
Astellas Pharma Global Development, Inc.Completed
-
Astellas Pharma Global Development, Inc.CompletedAdvanced Solid Tumors | Pharmacokinetics of 14C-labeled GilteritinibUnited States
-
Astellas Pharma IncCompleted
-
Astellas Pharma Global Development, Inc.CompletedAcute Myeloid Leukemia | Advanced Solid TumorsUnited States
-
Etan OrgelAstellas Pharma Global Development, Inc.No longer available
-
Astellas Pharma Global Development, Inc.CompletedRenal Impaired | Gilteritinib | Normal Renal Function | Pharmacokinetics of ASP2215United States, Bulgaria
-
University of Rome Tor VergataActive, not recruiting
-
Astellas Pharma Global Development, Inc.No longer availableAcute Myeloid Leukemia (AML) | FMS-like Tyrosine Kinase-3 (FLT3) MutationsAustralia, Italy, United Kingdom
-
Astellas Pharma Global Development, Inc.Approved for marketingAcute Myeloid Leukemia (AML) | FMS-like Tyrosine Kinase-3 (FLT3) MutationsUnited States, Canada, Japan
-
Astellas Pharma Global Development, Inc.National Heart, Lung, and Blood Institute (NHLBI); Blood and Marrow Transplant...CompletedAcute Myeloid LeukemiaUnited States, Japan, Korea, Republic of, Taiwan, Spain, Italy, United Kingdom, Australia, Belgium, Canada, Denmark, France, Germany, Greece, New Zealand, Poland